Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

An EP4 antagonist ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer.

Xu S, Zhang Z, Ogawa O, Yoshikawa T, Sakamoto H, Shibasaki N, Goto T, Wang L, Terada N.

Cell Biochem Biophys. 2014 Sep;70(1):521-7. doi: 10.1007/s12013-014-9951-2.

PMID:
24744183
2.

Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.

Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, Kobayashi T, Nakamura E, Kamoto T, Kanaji T, Maruyama T, Mikami Y, Toda Y, Matsuoka T, Okuno Y, Tsujimoto G, Narumiya S, Ogawa O.

Cancer Res. 2010 Feb 15;70(4):1606-15. doi: 10.1158/0008-5472.CAN-09-2984. Epub 2010 Feb 9.

3.

[Inhibitory effect of ONO-AE3-208 on the formation of bone metastasis of prostate cancer in mice].

Xu S, Ge JP, Zhou WQ, Zhang ZY.

Zhonghua Nan Ke Xue. 2014 Aug;20(8):684-9. Chinese.

PMID:
25195362
4.

Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism.

Yang L, Huang Y, Porta R, Yanagisawa K, Gonzalez A, Segi E, Johnson DH, Narumiya S, Carbone DP.

Cancer Res. 2006 Oct 1;66(19):9665-72.

5.

[Novel treatment for prostate cancer targeting prostaglandins].

Terada N, Inoue T, Kamba T, Ogawa O.

Nihon Rinsho. 2014 Dec;72(12):2141-6. Japanese.

PMID:
25518348
6.

Inhibition of EP4 signaling attenuates aortic aneurysm formation.

Yokoyama U, Ishiwata R, Jin MH, Kato Y, Suzuki O, Jin H, Ichikawa Y, Kumagaya S, Katayama Y, Fujita T, Okumura S, Sato M, Sugimoto Y, Aoki H, Suzuki S, Masuda M, Minamisawa S, Ishikawa Y.

PLoS One. 2012;7(5):e36724. doi: 10.1371/journal.pone.0036724. Epub 2012 May 3.

7.

Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.

Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK.

Lab Invest. 2012 Aug;92(8):1115-28. doi: 10.1038/labinvest.2012.90. Epub 2012 May 28.

8.

LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.

Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW.

Prostate. 2000 Jul 1;44(2):91-103 Jul 1;44(2).

PMID:
10881018
9.

Abrogation of prostaglandin E-EP4 signaling in osteoblasts prevents the bone destruction induced by human prostate cancer metastases.

Watanabe K, Tominari T, Hirata M, Matsumoto C, Maruyama T, Murphy G, Nagase H, Miyaura C, Inada M.

Biochem Biophys Res Commun. 2016 Sep 9;478(1):154-161. doi: 10.1016/j.bbrc.2016.07.075. Epub 2016 Jul 19.

PMID:
27450806
10.

SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis.

Rabbani SA, Valentino ML, Arakelian A, Ali S, Boschelli F.

Mol Cancer Ther. 2010 May;9(5):1147-57. doi: 10.1158/1535-7163.MCT-09-0962. Epub 2010 Apr 27.

11.

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.

Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, Chung LW.

J Natl Cancer Inst. 1996 Jun 19;88(12):794-801.

PMID:
8637045
12.

The PGE(2)-EP4 receptor is necessary for stimulation of the renin-angiotensin-aldosterone system in response to low dietary salt intake in vivo.

Pöschke A, Kern N, Maruyama T, Pavenstädt H, Narumiya S, Jensen BL, Nüsing RM.

Am J Physiol Renal Physiol. 2012 Nov 15;303(10):F1435-42. doi: 10.1152/ajprenal.00512.2011. Epub 2012 Sep 19.

13.

Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.

Laurenzana A, Balliu M, Cellai C, Romanelli MN, Paoletti F.

PLoS One. 2013;8(3):e58267. doi: 10.1371/journal.pone.0058267. Epub 2013 Mar 4.

14.

Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis.

Ma X, Kundu N, Rifat S, Walser T, Fulton AM.

Cancer Res. 2006 Mar 15;66(6):2923-7.

15.

Prostaglandin E receptor EP4 antagonist suppresses osteolysis due to bone metastasis of mouse malignant melanoma cells.

Takita M, Inada M, Maruyama T, Miyaura C.

FEBS Lett. 2007 Feb 6;581(3):565-71. Epub 2007 Jan 16.

16.

Prostaglandin EP4 receptor enhances BCR-induced apoptosis of immature B cells.

Prijatelj M, Celhar T, Mlinaric-Rascan I.

Prostaglandins Other Lipid Mediat. 2011 Aug;95(1-4):19-26. doi: 10.1016/j.prostaglandins.2011.04.001. Epub 2011 May 10.

PMID:
21600299
17.

Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis.

Esaki Y, Li Y, Sakata D, Yao C, Segi-Nishida E, Matsuoka T, Fukuda K, Narumiya S.

Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12233-8. doi: 10.1073/pnas.0915112107. Epub 2010 Jun 21.

18.

CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion.

Singh S, Singh UP, Grizzle WE, Lillard JW Jr.

Lab Invest. 2004 Dec;84(12):1666-76.

19.

Significance of divergent expression of prostaglandin EP4 and EP3 receptors in human prostate cancer.

Huang HF, Shu P, Murphy TF, Aisner S, Fitzhugh VA, Jordan ML.

Mol Cancer Res. 2013 Apr;11(4):427-39. doi: 10.1158/1541-7786.MCR-12-0464. Epub 2013 Jan 30.

20.

Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.

Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM, Chen Y, Qin GJ, Liang G, Li JN, Han XF, Liu DX.

Mol Immunol. 2009 Sep;46(15):2876-84. doi: 10.1016/j.molimm.2009.06.016. Epub 2009 Jul 29.

PMID:
19643479

Supplemental Content

Support Center